Delayed GN Hearing device sent for FDA evaluation

Hearing device Jabra Enhance Plus, which GN Hearing is hoping will open up a new market, has been submitted to the US Food and Drug Administration for assessment. Earlier this month, product launch delays led to the head of reasearch and development being let go.
Photo: GN Hearing / PR
Photo: GN Hearing / PR
BY MIKKEL AABENHUS HEMMINGSEN, ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN

The launch of the new hearing device Jabra Enhance Plus, which is developed by GN Hearing, now depends on the US Food and Drug Administration (FDA), as the company has sent the product off for evaluation, CEO Gitte Aabo tells MedWatch in an interview.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading